Applied Proteomics

The firm is looking for outside partners to tackle test commercialization as it begins to bring its second-generation colorectal cancer assay to market.

The test, which the company aims to launch in the next few months, offers a boost in specificity compared to its existing SimpliPro Colon proteomic test.

Company officials said that they have seen favorable reorder rates and coverage decisions since launching the 11-protein colorectal cancer test in late 2015.

While the company had previously planned to launch on mass spec, it is using ELISA for the initial version of the test in a bid to bring it to market more quickly.

NEW YORK (GenomeWeb News) – Applied Proteomics today said that it will collaborate with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) on the discovery and development of molecular diagnostic tests for colon and pancreatic cancer.

Applied Proteomics said this week that it has closed a $28 million Series C financing round.

Bruker has appointed Thomas Bachmann to be president of its Bruker BioSpin Group.

NEW YORK (GenomeWeb News) – Applied Proteomics said today that it has closed a $28 million Series C financing round.

On a conference call last month following the release of its Q1 earnings, Vermillion CEO Thomas McLain announced that the company would be taking over from Quest Diagnostics as leader of commercialization efforts for its OVA1 ovarian cancer diagnostic (

In March 2010, Austin, Texas-based diagnostics firm Vermillion launched sales of its OVA1 ovarian cancer test.

Pages

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.